Theodore R Levin

List of Publications by Year
in descending order

113	21,920	28274	23533
papers	citations	55 h-index	111 g-index

118	118	118	15519
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Colorectal cancer screening and surveillance: Clinical guidelines and rationale?Update based on new evidence. Gastroenterology, 2003, 124, 544-560.	1.3	2,016
2	Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline From the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology, 2008, 134, 1570-1595.	1.3	2,002
3	Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 2012, 143, 844-857.	1.3	1,717
4	Adenoma Detection Rate and Risk of Colorectal Cancer and Death. New England Journal of Medicine, 2014, 370, 1298-1306.	27.0	1,653
5	Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Ca-A Cancer Journal for Clinicians, 2008, 58, 130-160.	329.8	1,491
6	Multitarget Stool DNA Testing for Colorectal-Cancer Screening. New England Journal of Medicine, 2014, 370, 1287-1297.	27.0	1,352
7	Quality in the technical performance of colonoscopy and the continuous quality improvement process for colonoscopy: recommendations of the U.S. Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2002, 97, 1296-1308.	0.4	961
8	Poor Survival Associated with the BRAF V600E Mutation in Microsatellite-Stable Colon Cancers. Cancer Research, 2005, 65, 6063-6069.	0.9	701
9	Accuracy of Fecal Immunochemical Tests for Colorectal Cancer. Annals of Internal Medicine, 2014, 160, 171-181.	3.9	528
10	Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 2017, 153, 307-323.	1.3	512
11	Complications of Colonoscopy in an Integrated Health Care Delivery System. Annals of Internal Medicine, 2006, 145, 880.	3.9	489
12	Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2017, 112, 1016-1030.	0.4	483
13	Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society TaskÂForce on Colorectal Cancer. Gastroenterology, 2014, 147, 502-526.	1.3	397
14	Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2014, 109, 1159-1179.	0.4	363
15	Screening for Colorectal Neoplasms With New Fecal Occult Blood Tests: Update on Performance Characteristics. Journal of the National Cancer Institute, 2007, 99, 1462-1470.	6.3	346
16	Effects of Organized Colorectal Cancer Screening on Cancer Incidence and Mortality in a Large Community-Based Population. Gastroenterology, 2018, 155, 1383-1391.e5.	1.3	329
17	Optimizing Adequacy of Bowel Cleansing for Colonoscopy: Recommendations From the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 2014, 147, 903-924.	1.3	322
18	Incidence and Mortality of Colorectal Adenocarcinoma in Persons With Inflammatory Bowel Disease From 1998 to 2010. Gastroenterology, 2012, 143, 382-389.	1.3	273

#	Article	IF	Citations
19	Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 2017, 152, 1217-1237.e3.	1.3	268
20	Effectiveness of screening colonoscopy in reducing the risk of death from right and left colon cancer: a large community-based study. Gut, 2018, 67, 291-298.	12.1	264
21	Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. Gastrointestinal Endoscopy, 2007, 65, 757-766.	1.0	258
22	Stool DNA and Occult Blood Testing for Screen Detection of Colorectal Neoplasia. Annals of Internal Medicine, 2008, 149, 441.	3.9	244
23	Association Between Time to Colonoscopy After a Positive Fecal Test Result and Risk of Colorectal Cancer and Cancer Stage at Diagnosis. JAMA - Journal of the American Medical Association, 2017, 317, 1631.	7.4	198
24	Variation of Adenoma Prevalence by Age, Sex, Race, and Colon Location in a Large Population: Implications for Screening and Quality Programs. Clinical Gastroenterology and Hepatology, 2013, 11, 172-180.	4.4	197
25	Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening. Annals of Internal Medicine, 2016, 164, 456.	3.9	186
26	Public health impact of achieving 80% colorectal cancer screening rates in the United States by 2018. Cancer, 2015, 121, 2281-2285.	4.1	180
27	Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. International Journal of Cancer, 2007, 120, 656-663.	5.1	177
28	Shifts in the Fecal Microbiota Associated with Adenomatous Polyps. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 85-94.	2.5	168
29	Predicting Advanced Proximal Colonic Neoplasia With Screening Sigmoidoscopy. JAMA - Journal of the American Medical Association, 1999, 281, 1611.	7.4	163
30	Organized Colorectal Cancer Screening in Integrated Health Care Systems. Epidemiologic Reviews, 2011, 33, 101-110.	3.5	163
31	Colonoscopy Surveillance After Colorectal Cancer Resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 2016, 150, 758-768.e11.	1.3	151
32	Colorectal cancer screening: Recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastrointestinal Endoscopy, 2017, 86, 18-33.	1.0	145
33	Screening Colonoscopy and Risk for Incident Late-Stage Colorectal Cancer Diagnosis in Average-Risk Adults. Annals of Internal Medicine, 2013, 158, 312.	3.9	142
34	Optimizing Adequacy of Bowel Cleansing for Colonoscopy: Recommendations From the US Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2014, 109, 1528-1545.	0.4	119
35	Optimizing adequacy of bowel cleansing for colonoscopy: recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastrointestinal Endoscopy, 2014, 80, 543-562.	1.0	106
36	Time to Colonoscopy after Positive Fecal Blood Test in Four U.S. Health Care Systems. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 344-350.	2.5	106

#	Article	IF	Citations
37	Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a Health Maintenance Organization. American Journal of Gastroenterology, 2000, 95, 788-792.	0.4	104
38	Complications of screening flexible sigmoidoscopy. Gastroenterology, 2002, 123, 1786-1792.	1.3	103
39	Costs of Acid-Related Disorders to a Health Maintenance Organization. American Journal of Medicine, 1997, 103, 520-528.	1.5	102
40	Colorectal cancer deaths attributable to nonuse of screening in the United States. Annals of Epidemiology, 2015, 25, 208-213.e1.	1.9	102
41	Current and future colorectal cancer screening strategies. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 521-531.	17.8	102
42	Genetic polymorphisms in one-carbon metabolism: associations with CpG island methylator phenotype (CIMP) in colon cancer and the modifying effects of diet. Carcinogenesis, 2007, 28, 1672-1679.	2.8	93
43	Interventions to Improve Follow-up of Positive Results on Fecal Blood Tests. Annals of Internal Medicine, 2017, 167, 565.	3.9	91
44	Long-term Risk of Colorectal Cancer and Related Death After Adenoma Removal in a Large, Community-based Population. Gastroenterology, 2020, 158, 884-894.e5.	1.3	85
45	Omeprazole Improves Peak Expiratory Flow Rate and Quality of Life in Asthmatics With Gastroesophageal Reflux. American Journal of Gastroenterology, 1998, 93, 1060-1063.	0.4	84
46	Dietary Antioxidants, Fruits, and Vegetables and the Risk of Barrett's Esophagus. American Journal of Gastroenterology, 2008, 103, 1614-1623.	0.4	80
47	Modifiable Failures in the Colorectal Cancer Screening Process and Their Association With Risk of Death. Gastroenterology, 2019, 156, 63-74.e6.	1.3	78
48	Change in Body Size and the Risk of Colorectal Adenomas. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 526-531.	2.5	77
49	Mailed fecal immunochemical test outreach for colorectal cancer screening: Summary of a Centers for Disease Control and Preventionâ€“sponsored Summit. Ca-A Cancer Journal for Clinicians, 2020, 70, 283-298.	329.8	75
50	Diagnosis, Comorbidities, and Management of Irritable Bowel Syndrome in Patients in a Large Health Maintenance Organization. Clinical Gastroenterology and Hepatology, 2012, 10, 37-45.	4.4	72
51	Variation in Adenoma Detection Rate and the Lifetime Benefits and Cost of Colorectal Cancer Screening. JAMA - Journal of the American Medical Association, 2015, 313, 2349.	7.4	72
52	The Colorectal Cancer Screening Process in Community Settings: A Conceptual Model for the Population-Based Research Optimizing Screening through Personalized Regimens Consortium. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1147-1158.	2.5	64
53	Associations between apoE genotype and colon and rectal cancer. Carcinogenesis, 2005, 26, 1422-1429.	2.8	61
54	Colonoscopy Surveillance after Colorectal Cancer Resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2016, 111, 337-346.	0.4	59

#	Article	IF	Citations
55	Screening in liver disease: Report of an AASLD clinical workshop. Hepatology, 2004, 39, 1204-1212.	7.3	57
56	Long-term Risk of Colorectal Cancer and Related Deaths After a Colonoscopy With Normal Findings. JAMA Internal Medicine, 2019, 179, 153.	5.1	57
57	A Comparison of Fecal Immunochemical and High-Sensitivity Guaiac Tests for Colorectal Cancer Screening. American Journal of Gastroenterology, 2017, 112, 1728-1735.	0.4	56
58	Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2017, 112, 37-53.	0.4	56
59	Recommendations on fecal immunochemical testing to screen forÂcolorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastrointestinal Endoscopy, 2017, 85, 2-21.e3.	1.0	55
60	Quality in the technical performance of screening flexible sigmoidoscopy: recommendations of an international multi-society task group. Gut, 2005, 54, 807-813.	12.1	51
61	Race/Ethnicity and Adoption of a Population Health Management Approach to Colorectal Cancer Screening in a Community-Based Healthcare System. Journal of General Internal Medicine, 2016, 31, 1323-1330.	2.6	50
62	Quality of Life Measurement Clarifies The Cost-Effectiveness of Helicobacter Pylori Eradication in Peptic Ulcer Disease and Uninvestigated Dyspepsia. American Journal of Gastroenterology, 2001, 96, 338-347.	0.4	48
63	Influence of Varying Quantitative Fecal Immunochemical Test Positivity Thresholds on Colorectal Cancer Detection. Annals of Internal Medicine, 2018, 169, 439-447.	3.9	47
64	Interactions Between CYP2C9 and UGT1A6 Polymorphisms and Nonsteroidal Anti-Inflammatory Drugs in Colorectal Cancer Prevention. Clinical Gastroenterology and Hepatology, 2006, 4, 894-901.	4.4	46
65	PPARÎ³ and Colon and Rectal Cancer: Associations with Specific Tumor Mutations, Aspirin, Ibuprofen and Insulin-Related Genes (United States). Cancer Causes and Control, 2006, 17, 239-249.	1.8	44
66	Health Benefits and Cost-effectiveness of a Hybrid Screening Strategy for Colorectal Cancer. Clinical Gastroenterology and Hepatology, 2013, 11, 1158-1166.	4.4	40
67	Hepatic Effects of Lovastatin Exposure in Patients with Liver Disease. Drug Safety, 2008, 31, 325-334.	3.2	31
68	Diagnosis and predictors of sessile serrated adenoma after educational training in a large, community-based, integrated healthcareÂsetting. Gastrointestinal Endoscopy, 2018, 87, 755-765.e1.	1.0	28
69	Association between Improved Colorectal Screening and Racial Disparities. New England Journal of Medicine, 2022, 386, 796-798.	27.0	28
70	Strategies to Improve Follow-up After Positive Fecal Immunochemical Tests in a Community-Based Setting: A Mixed-Methods Study. Clinical and Translational Gastroenterology, 2019, 10, e00010.	2.5	27
71	Increased Risk of Colorectal Cancer in Individuals With a History of Serrated Polyps. Gastroenterology, 2020, 159, 502-511.e2.	1.3	27
72	Development and validation of an algorithm for classifying colonoscopy indication. Gastrointestinal Endoscopy, 2015, 81, 575-582.e4.	1.0	26

#	Article	IF	Citations
73	Automated phone and mail population outreach to promote colorectal cancer screening. American Journal of Managed Care, 2012, 18, 370-8.	1.1	26
74	Effectiveness and Reach of the FLU-FIT Program in an Integrated Health Care System: A Multisite Randomized Trial. American Journal of Public Health, 2013, 103, 1128-1133.	2.7	25
75	Fecal Immunochemical Test (FIT) for Colon Cancer Screening: Variable Performance with Ambient Temperature. Journal of the American Board of Family Medicine, 2016, 29, 672-681.	1.5	24
76	Accurate Identification of Colonoscopy Quality and Polyp Findings Using Natural Language Processing. Journal of Clinical Gastroenterology, 2019, 53, e25-e30.	2.2	24
77	Program Components and Results From an Organized Colorectal Cancer Screening Program Using Annual Fecal Immunochemical Testing. Clinical Gastroenterology and Hepatology, 2022, 20, 145-152.	4.4	21
78	Improved Marker Combination for Detection of De Novo Genetic Variation and Aberrant DNA in Colorectal Neoplasia. Clinical Chemistry, 2006, 52, 2299-2302.	3.2	20
79	Colonoscopy surveillance after colorectal cancer resection: recommendations of the US multi-society task force on colorectalÂcancer. Gastrointestinal Endoscopy, 2016, 83, 489-498.e10.	1.0	20
80	The Road Ahead: What if Gastroenterologists Were Accountable for Preventing Colorectal Cancer?. Clinical Gastroenterology and Hepatology, 2013, 11, 204-207.	4.4	18
81	Early Screening of African Americans (45â€“50 Years Old) in a Fecal Immunochemical Testâ€“Based Colorectal Cancer Screening Program. Gastroenterology, 2020, 159, 1695-1704.e1.	1.3	18
82	Impact of the COVID-19 Pandemic on Fecal Immunochemical Testing, Colonoscopy Services, and Colorectal Neoplasia Detection in a Large United States Community-based Population. Gastroenterology, 2022, 163, 723-731.e6.	1.3	18
83	Cimetidine Use and Risk of Breast, Prostate, and Other Cancers. , 2000, 9, 149-155.		17
84	Optimizing Colorectal Cancer Screening by Getting FIT Right. Gastroenterology, 2011, 141, 1551-1555.	1.3	17
85	Lack of significant association between serum inflammatory cytokine profiles and the presence of colorectal adenoma. BMC Cancer, 2015, 15, 123.	2.6	17
86	Flexible Sigmoidoscopy. Gastrointestinal Endoscopy Clinics of North America, 2002, 12, 23-40.	1.4	15
87	Performance of a quantitative fecal immunochemical test for detecting advanced colorectal neoplasia: a prospective cohort study. BMC Cancer, 2018, 18, 509.	2.6	15
88	What Is Organized Screening and What Is Its Value?. Gastrointestinal Endoscopy Clinics of North America, 2020, 30, 393-411.	1.4	15
89	Validation of an Algorithm to Identify Patients at Risk for Colorectal Cancer Based on Laboratory Test and Demographic Data in Diverse, Community-Based Population. Clinical Gastroenterology and Hepatology, 2020, 18, 2734-2741.e6.	4.4	14
90	Risk stratification for colorectal cancer in individuals with subtypes of serrated polyps. Gut, 2022, 71, 2022-2029.	12.1	14

#	Article	IF	Citations
91	Colorectal Cancer Screening Initiation After Age 50 Years in an Organized Program. American Journal of Preventive Medicine, 2017, 53, 335-344.	3.0	13
92	Implications of New Colorectal Cancer Screening Technologies for Primary Care Practice. Medical Care, 2008, 46, S138-S146.	2.4	12
93	Genetic Biomarker Prevalence Is Similar in Fecal Immunochemical Test Positive and Negative Colorectal Cancer Tissue. Digestive Diseases and Sciences, 2017, 62, 678-688.	2.3	12
94	Flexible sigmoidoscopy for colorectal cancer screening: valid approach or short-sighted?. Gastroenterology Clinics of North America, 2002, 31, 1015-1029.	2.2	9
95	Dealing With Uncertainty: Surveillance Colonoscopy After Polypectomy. American Journal of Gastroenterology, 2007, 102, 1745-1747.	0.4	9
96	Colorectal cancer screening: 80% by 2018. Colonoscopists simply cannot do it alone. Gastrointestinal Endoscopy, 2016, 83, 552-554.	1.0	9
97	Disparities in Preventable Mortality from Colorectal Cancer: Are They the Result of Structural Racism?. Gastroenterology, 2021, 160, 1022-1025.	1.3	9
98	Re: Risk of Perforation After Colonoscopy and Sigmoidoscopy: A Population-Based Study. Journal of the National Cancer Institute, 2003, 95, 830-831.	6.3	7
99	In Screening for Colorectal Cancer, Is the FIT Right for the Right Side of the Colon?. Annals of Internal Medicine, 2018, 169, 650.	3.9	7
100	The Importance of Choosing Colorectal Cancer Screening Tests. Archives of Internal Medicine, 2012, 172, 582.	3.8	6
101	Colorectal Cancer Screening Participation Among Asian Americans Overall and Subgroups in an Integrated Health Care Setting with Organized Screening. Clinical and Translational Gastroenterology, 2018, 9, e186.	2.5	6
102	CDC Grand Rounds: the future of cancer screening. Morbidity and Mortality Weekly Report, 2015, 64, 324-7.	15.1	5
103	Prevention of colorectal cancer through multiomics blood testing: The PREEMPT CRC study.. Journal of Clinical Oncology, 2022, 40, TPS208-TPS208.	1.6	5
104	Editorial: Taking FIT to the People: Out of the Office and Into the Mail. American Journal of Gastroenterology, 2012, 107, 108-110.	0.4	4
105	Colorectal Cancer Screening: Money Isnâ€™t Everything . . . ButÂItÂHelps!. Gastroenterology, 2017, 153, 1181-1183.	1.3	4
106	Balancing Adherence and Expense: The Cost-Effectiveness of Two-Sample vs One-Sample Fecal Immunochemical Test. Population Health Management, 2019, 22, 83-89.	1.7	4
107	Ten-year incidence of colorectal cancer following a negative screening sigmoidoscopy: an update from the Colorectal Cancer Prevention (CoCaP) programme. Gut, 2016, 65, 271-277.	12.1	3
108	What Does Sigmoidoscopy Really Miss?. American Journal of Gastroenterology, 2003, 98, 2326-2327.	0.4	2

#	Article	IF	Citations
109	Influence of Varying Quantitative Fecal Immunochemical Test Positivity Thresholds on Colorectal Cancer Detection. Annals of Internal Medicine, 2019, 170, 736.	3.9	2
110	Long-Term Drug Treatment of GERD. Disease Management and Health Outcomes, 2004, 12, 399-407.	0.4	1
111	The Best Laid Plans: Adaptation is an Essential Part of Going From Efficacy Research to Program Implementation. Gastroenterology, 2017, 152, 693-694.	1.3	1
112	In simulation modelling, there are multiple ways to effectively screen for colorectal cancer. Evidence-Based Medicine, 2017, 22, 59-59.	0.6	0
113	Simplifying ADR Reporting: A Worthy Goal, but the Devil is in the Details. Clinical Gastroenterology and Hepatology, 2021, 19, 1793-1795.	4.4	0